MaRS Discovery District, Toronto, ON; March 31, 2021 – Proteocyte AI, a personalized medicine and diagnostics company located at MaRS Centre, Toronto, ON, announces today that an abstract and poster titled “Assessing Risk of Oral Cancer Progression Using an S100A7 Immunohistochemical Signature-based Assay” will be presented at the American Head and Neck Society’s (AHNS) 10th International Conference on Head and Neck Cancer “Survivorship through Quality & Innovation”.
Dr. Mark Darling, a professor in Pathology at Western University (London, ON) and the presenting author of the abstract says: “I’m very excited to present some preliminary data around our Straticyte observational study which began back in 2015. This ongoing study involves patients from the general community, and while preliminary, the data so far indicates that Straticyte is more accurate at identifying lesions at true low-risk from elevated-risk of progressing to cancer.”
The AHNS Conference this year will be held between July 22 – 25 at the Hyatt Regency in Chicago, Illinois. It is an international conference that has been the world’s pre-eminent meeting for head and neck cancer since its inception in 1984 and is attended by nearly 2000 surgeons, oncologists, scientists and allied health professionals from around the world.
Proteocyte AI is a personalized medicine and diagnostics company located in MaRS Center, Toronto, ON. Proteocyte’s products help tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, Straticyte, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.